Vistagen Therapeutics, Inc. (VTGN)
After hours:
| Previous close | 4.8300 |
| Open | 4.8500 |
| Bid | 4.7000 x 300 |
| Ask | 4.7500 x 200 |
| Day's range | 4.7200 - 4.9200 |
| 52-week range | 1.6200 - 24.7100 |
| Volume | |
| Avg. volume | 264,391 |
| Market cap | 128.099M |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
30 Countries with the Lowest Depression Rates
In this article, we will be taking a look at the 30 countries with the lowest depression rates. If you do not want to learn about the global depression treatment market, head straight to the 5 Countries with the Lowest Depression Rates. In countries with the lowest depression rates, individuals experience lower prevalence rates of […]
- Zacks
Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?
The mean of analysts' price targets for VistaGen Therapeutics, Inc. (VTGN) points to a 160% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Insider Monkey
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call Transcript
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call Transcript February 13, 2024 VistaGen Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.22, expectations were $-0.31. VTGN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to Vistagen Therapeutics’ […]
